Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the ...

The 12-month open-label extension of the PACIFIC trial demonstrated that bexicaserin significantly reduced seizure frequency ...

DelveInsight's“Lennox–Gastaut syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Lennox–Gastaut syndrome, historical and forecasted ...

The St. Louis Business Journal's Innovation in Philanthropy Awards program, now in its sixth year, celebrates local ...

The proposed study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg over 52-weeks compared to sham in children and adolescents ages 2 to <18 with Dravet syndrome.

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive ...

This trial will investigate zorevunersen as a potential treatment for Dravet syndrome, a severe form of epilepsy in children. The study, slated to begin in mid-2025, will assess the efficacy of ...

for zorevunersen for the treatment of Dravet syndrome with a confirmed mutation, not associated with gain-of-function, in the SCN1A gene. Zorevunersen is being developed as potentially BEDFORD ...

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...

ScienceAlert reports how a team of researchers in Brazil found that the fruits and flowers of Trema micrantha blume — a type ...

Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB ...

Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show. The BECOME-TSC study evaluated outcomes of Epidiolex (Jazz ...